Vitamin K prophylaxis for preterm infants: a randomized, controlled trial of 3 regimens

Paul Clarke1, Simon J Mitchell, Robert Wynn

  • 1Neonatal Unit, Hope Hospital, Salford, United Kingdom. paul.clarke@nnuh.nhs.uk

Pediatrics
|November 15, 2006
PubMed

Insights

Intramuscular vitamin K1 prophylaxis (0.2 mg) adequately maintained vitamin K status in preterm infants. Higher doses or intravenous administration led to vitamin K1 2,3-epoxide accumulation, suggesting potential liver overload.

Area of Science:

  • Neonatology
  • Pediatric Pharmacology
  • Biochemistry

Background:

  • Preterm infants face risks from both insufficient and excessive vitamin K prophylaxis.
  • Optimal vitamin K prophylaxis is crucial for preventing bleeding disorders in vulnerable newborns.

Purpose of the Study:

  • To evaluate vitamin K status and metabolism in preterm infants receiving different vitamin K1 prophylaxis regimens.
  • To compare serum vitamin K1, its epoxide metabolite, and prothrombin status across varied prophylaxis protocols.

Main Methods:

  • Randomized controlled trial involving preterm infants (<32 weeks gestation).
  • Three prophylaxis groups: 0.5 mg IM, 0.2 mg IM, and 0.2 mg IV vitamin K1.
  • Serum vitamin K1, vitamin K1 2,3-epoxide, and undercarboxylated prothrombin measured at birth, day 5, and 2 weeks post-enteral feeds.

Main Results:

  • Serum vitamin K1 levels were significantly higher than adult ranges in all groups on day 5.
  • Vitamin K1 2,3-epoxide accumulation was associated with higher IM doses (0.5 mg) and IV administration (0.2 mg).
  • Intramuscular 0.2 mg vitamin K1 maintained adequate status without epoxide accumulation; however, some infants showed undetectable levels by week 3.

Conclusions:

  • Intramuscular 0.2 mg vitamin K1 is effective for preterm infants, avoiding early epoxide accumulation.
  • Intravenous 0.2 mg and intramuscular 0.5 mg vitamin K1 may lead to immature liver overload.
  • Breastfed preterm infants receiving 0.2 mg prophylaxis may require additional supplementation to prevent late vitamin K deficiency bleeding.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...